The phosphoinositide 3-kinase pathway and therapy resistance in cancer.

    Thumbnail
    Download
    Citations
    Scopus
    Altmetric
    67
    Author
    Brown, KK; Toker, A
    Date
    2015
    Source Title
    F1000prime reports
    Publisher
    Faculty Opinions Ltd
    University of Melbourne Author/s
    Brown, Kristin
    Affiliation
    Biochemistry and Molecular Biology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Brown, K. K. & Toker, A. (2015). The phosphoinositide 3-kinase pathway and therapy resistance in cancer.. F1000Prime Rep, 7, pp.13-. https://doi.org/10.12703/P7-13.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/257552
    DOI
    10.12703/P7-13
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335789
    Abstract
    The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in cancer, and highlights potential combination therapy strategies to circumvent resistance driven by PI3K signaling. In addition, resistance mechanisms that limit the clinical efficacy of small molecule inhibitors of the PI3K pathway are discussed.

    Export Reference in RIS Format     

    Collections